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1. Introduction 
Despite significant advances in tumor imaging, neurosurgery, and radiotherapy, the 
prognosis for patients with malignant gliomas is extremely poor. The five-year survival rate 
for patients with glioblastoma (GBM), the most aggressive form of malignant glioma, is less 
than 5% after initial diagnosis (CBTRUS statistical report, 2010).  Factors that contribute to 
the dismal prognosis associated with GBM include its infiltrative nature throughout the 
brain, which precludes total surgical resection and impair radiotherapy targeting, and 
resistance to most types of conventional cancer therapeutics.  Many clinical studies using 
potent chemotherapeutic drugs conducted in the past decade have not demonstrated 
significant improvement in survival.  A fundamental limitation in the treatment of brain 
tumors is that many systemically administered therapeutic agents do not cross the blood-
brain barrier (BBB) (Abbott et al., 2010; Brightman, 1977; Huynh et al., 2006; Schlosshauer, 
1993). While some small and lipophilic molecules, peptides, and protein-based agents 
delivered by systemic routes can reach the brain parenchyma by crossing the BBB, high 
doses are usually needed to achieve therapeutic levels, which can lead to substantial 
toxicity.   
In this chapter, the application of intranasal delivery (IND), in comparison with systemic 
(intravascular) and/or direct invasive (intraparechymal) drug delivery, for the treatment of 
brain tumors is discussed. 
2. The BBB: An obstacle for drug delivery to brain tumor  
The brain parenchyma has both physiological and biological safeguards to prevent the entry 
of toxins from the bloodstream, which are collectively known as the BBB. The endothelial 
cells that comprise the cerebral micro-vessels are linked by tight junctions and surrounded 
by astrocytic processes and adjacent pericytes and a characteristic composition of the 
extracellular matrix. This structural arrangement prohibits most drugs from entering the 
brain through pericellular diffusion.  Drugs that are able to diffuse through the barrier must 
be small (<400 Da) and lipophilic.  In addition to this physiological barrier, drugs are rapidly 
cleared by efflux pumps such as P-glycoprotein, and a rapid turnover rate of extracellular 
fluid in the brain.  In combination, these factors have limited the number of successful 
pharmacologic treatments for diseases of the brain and necessitate a closer examination of 
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both traditional and novel methods of drug delivery (Choi et al., 2008; Eyal et al., 2009; 
Saunders et al., 2008).  
In brain tumors such as GBM, the BBB is progressively disrupted with tumor growth by 
inducing large gaps between endothelial cells (Coomber et al., 1985). However, the extent of 
BBB disruption among individual patients, and/or among various regions within a single 
tumor, appears to be highly variable. BBB is most likely disrupted in the necrotic center, not 
at the infiltrative edge of the tumor (Gerstner & Fine, 2007). Recently, the artificially 
disruption of the BBB using hyper osmotic solutions has demonstrated by intra-arterial 
infusion of the VEGF specific antibody bevacizumab in patients with recurrent malignant 
glioma (Boockvar et al., 2010).  However, disruption of the BBB could potentially lead to 
other serious complications, such as brain edema. Therefore, development of strategies to 
deliver targeted agents across the BBB is a critical priority. 
3. Strategies for drug delivery to the brain  
In the past decade a number of drug delivery strategies have been developed to overcome 
challenges presented by BBB. These strategies can be divided into two categories: (a) 
attempt to increase drug delivery of intravascularly administered drugs by manipulating 
either the drugs or capillary permeability, and (b) attempt to increase drug delivery by local 
administration.   
3.1 Intravascular delivery  
Several strategies have recently developed to increase the fraction of intravascular drug 
reaching the tumor.  These include i) intra-arterial administration, ii) packaging drugs such 
as microcapsules and liposomes, iii) use of biologically active agents (such as bradykinin 
and histamine) (Greenwood, 1992), iv) use of replication-competent retroviruses to deliver 
oncolytic therapies (Tai & Kasahara, 2008), v) use of mesenchymal (Yong et al., 2009) or 
neural stem cells to deliver small molecules, antibodies, or toxic payloads (Aboody et al., 
2000; Frank et al., 2009). There are also several specific transport mechanisms that have been 
exploited, involving the activity of several independent transporters that mediate the flux of 
substances important for brain function, such as carrier-mediated transporters, including the 
glucose and amino acid transporters (Rapoport, 1996; Tamai & Tsuji, 1996; Deeken & 
Loscher, 2007; Saunders et al., 2008), active efflux transporters, including P-glycoprotein and 
the other ATP-binding cassette (ABC) gene family members, and receptor-mediated 
transporters, of which transferrin receptor (TfR), insulin receptor, and low-density 
lipoprotein receptor (Pardridge, 2007). A further strategy has been to conjugate the 
therapeutic drug with a protein or a monoclonal antibody that gains access to the brain by 
receptor-mediated transcytosis (Pardridge, 1999).  Small peptide vectors have been used to 
enhance brain uptake of several therapeutic drugs (Rousselle et al., 2000). These peptide-
vectors cross cellular membranes safely and efficiently and have been used successfully to 
enhance penetration of several drugs.   
The strategy of a packaging drugs and/or interfering RNAs into liposomes that more 
readily cross the BBB and show tumor reduction and increase in survival in mice.  
Liposomes are a drug carrier system consisting of a phospholipid membrane shell 
surrounding a hollow core used to stably encapsulate therapeutic molecules allowing 
increased solubility and half-life resulting in increased bioavailability.  Gradual release of 
the drug from the liposome increases therapeutic efficacy while reducing toxicity (Gabizon, 
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2003). Liposomal anticancer agents have been widely used in humans and are currently 
approved for ovarian cancer (Tanguay, 2009) and multiple myeloma (Moreau, 2009), but 
remain investigational in their use for brain tumors.  To increase the specificity of liposomal 
drugs, targeting antibodies can be attached to the surface of the liposome (Elbayoumi & 
Torchilin, 2009; Mamot et al., 2005).  Antibody-conjugated liposomes increase the rate of 
liposome internalization, which increase intracellular drug concentration, thereby achieving 
heightened anti-tumor activity (Mamot et al., 2005).  EGFR, a tyrosine kinase receptor that is 
over-expressed in 30-40% of high grade gliomas (Ekstrand et al., 1991).  Attempts to target 
GBM by delivering EGFR-targeted immunoliposomes encapsulated anti-cancer agents or 
EGFR-specific shRNA in PEGylated liposomes bearing insulin receptor– and TfR-specific 
antibodies in an in vivo model has shown some promise (Mamot et al., 2005; Zhang et al., 
2004). However, these antibody-based approaches have yet to translate into the clinic. 
Developing the right targeting antibodies to facilitate crossing of the BBB in humans, and 
uncovering the molecular mechanism by which the process works, remain significant 
impediments to clinical application.  
3.2 Convection-enhanced delivery  
Technology to improve direct drug delivery into the central nervous system (CNS) are 
currently part of intensive research, and include intraventricular or intraparenchymal 
injections [e.g. convection-enhanced delivery (CED)].  In particular, CED has shown 
promising results in both animal models and clinical trials (Huynh et al., 2006; Kawakami et 
al., 2004; MacKay et al., 2005; Mamot et al., 2004; Ozawa et al., 2002; Saito et al., 2006). CED 
is a continuous infusion that uses a convective (versus diffusive) flow to drive the 
therapeutic agent throughout a larger region of tissue.  CED uses a slow drug infusion rate 
by micro infusion pump coupled with a specially designed catheter which is a 1-mm 
stepped design with a fused silica tubing into 24 gage needle.  These optimal CED devices 
increase drug distribution and reduce reflux (Serwer et al., 2010) (Figure 1,2).  
 
 
Fig. 1. CED cannula and surgical set-up. 
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CED is well suited for the delivery of liposomes and particulate drug carriers which have 
the potential to provide a sustained level of drug and to reach cellular targets with 
improved specificity (Murad et al., 2006; Saito et al., 2004).  CED of liposomal anti-cancer 
agents have shown greater brain and tumor retention, and effective anti-tumor activity in 
GBM xenografted animals, as compared to free drugs delivery (Bidros & Vogelbaum, 2009; 
Noble et al., 2006; Yamashita et al., 2007).  Importantly, prolonged exposure to liposomal 
anti-cancer agents resulted in no measurable CNS toxicity, whereas free drugs induced 
severe CNS toxicity.  
 
 
Fig. 2. Representative image of successful CED into the mice brain tumor. 
CED has also been used to deliver larger particles, including purified virus and proteins.  
Currently, CED is being evaluated in 17 clinical trials for the delivery of small molecules, 
antisense oligonucleotides, and proteins (United States National Institutes of Health, 2011).  
However, this technique requires the use of potentially risky surgical procedures to position 
the catheter into the patient’s brain parenchyma, and is expensive techniques.  Additional 
limitations of these methods are inadequate CNS distribution due to reflux and leakage 
along with the needle tracts from the injection site and rapid turnover of the cerebrospinal 
fluid (CSF). The reflux and leakage through the implanted catheter leads to a measurable 
and significant inflammation and local edema, because drug solution infuse continuously 
beyond the tumor boundary into adjacent normal brain tissues (Kawakami et al., 2004; 
Marmot et al., 2004; Ozawa et al., 2004; Sandberg et al., 2002).  Finally, CED infusions can be 
variable by investigators, in one study the rate of successful infusion was reported as 19% 
(Sampson et al., 2008).  
3.3 Intranasal delivery 
One technique under current investigations is to integrate a recent innovation in drug delivery 
to the brain, intranasal delivery (IND).  IND is a practical and noninvasive method of 
bypassing the BBB and eliminating the surgical risk associated with direct drug administration 
into the brain parenchyma. It is an alternative to systemic (intravascular) and/or direct 
invasive (intraparechymal) drug delivery. IND relies upon the unique anatomic connections of 
Tumor 
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the olfactory and trigeminal nerves from the nasal mucosa to the CNS (Dhuria et al., 2010; 
Thorne et al., 2004).  These nerves arise in the brainstem and innervate the nasal mucosa, 
allowing detection of odors and other sensory stimuli (Dhanda et al., 2006; Thorne et al., 2004). 
Intranasally administered drugs reach the CNS and/or CSF within minutes of administration 
by using an extracellular route through perineural and perivascular channels, without binding 
to any receptor or relying upon axonal transport (Dhuria et al., 2010; Thorne et al., 2004) 
(Figure 3a). To administer the drugs through the nasal cavity, animals were anesthetized with 
2–2.5% isoflurane and placed in an anesthesia chamber. Six µl drops of soluble form of 
therapeutic agents were administered with a small pipette every 2 min into alternate sides of 
the nasal cavity for a total of 22 min (a total volume of 66 µl). This method of administration 
results in consistent deposition in the olfactory epithelium without respiratory distress. 
Following IND, the animals remained in a supine position for 15 min in order for absorption to 
occur through the nasal mucosa (Figure 3b). 
 
 
(a) Anatomical pathways of IND 
 
 
 (b) IND in athymic rats 
Fig. 3. (a) Anatomic and extraneuronal pathways of the olfactory and trigeminal nerves 
following IND (b) Demonstration of IND in an anesthetized athymic rat. 
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In addition to bypassing the BBB, advantages of IND are the avoidance of hepatic first-pass 
elimination, thereby reducing systemic side effects, and convenient self-administration for 
patients, a feature that would clearly aid in clinical applications, particularly in the 
treatment of brain tumors where repeated dosing is necessary (Dhuria et al., 2010).  
Many therapeutic agents, including small molecules, growth factors, proteins, peptides, 
viral vectors, liposomes, nanoparticles and vaccines, have been delivered into the CNS in 
both animals and humans using IND for a variety of CNS disorders.  Thorne et al reported 
that IGF-1 can be rapidly transported into the rat brain and upper spinal cord via the 
olfactory and trigeminal pathways (Thorne et al., 2004) and, IFNβ-1b can be delivered into 
the CNS in monkeys (Thorne et al., 2008). Furthermore, rat mesenchymal stem cells and 
human glioma cells have been delivered to the brain through the nasal pathway (Danielyan 
et al, 2009). In humans, IND with insulin improves memory in healthy adults (Banks et al., 
2004; Benedict et al., 2004) and in patients with early-stage Alzheimer's disease (Reger et al., 
2008) without changing the blood levels of glucose or insulin.  Also, IND with the 
neuropeptide oxytocin has been reported to improve trust (Baumgartner et al., 2008; Kosfeld 
et al, 2005), social behavior (Domes et al., 2007a, 2007b; Guastella et al., 2009), and social 
memory (Rimmele et al., 2009), and decreased fear and anxiety (Kirsch et al., 2005; Parker et 
al., 2005).   
In brain tumor model, many anti-cancer agents such as methotrexate (Shingaki et al., 1999; 
Shingaki et al., 2010), 5-fluorouracil (Sakane et al., 1999) and raltitrexed (Wang et al., 2005) 
have been delivered successfully to the brain using IND.  Shingaki et al reported that 
intranasally delivered methotrexate reached the CSF and reduced tumor weight in rodent 
glioma allografts (Shingaki et al., 1999). Drug targeting of the chemotherapeutic agent 
raltitrexed to the brain was significantly higher following IND compared with that of 
intravenous administration (Wang et al., 2005). However, these chemotherapeutic agents do 
not discriminate between tumor and normal tissues. Thus, the application of drugs at 
concentrations required to kill tumor cells can also lead to toxicity in normal neural tissues. 
To achieve therapeutic efficacy without toxicity, the drugs need to preferentially target brain 
tumors while sparing normal tissue from damage. 
3.3.1 Intranasal delivery of a telomerase inhibitor 
Given that telomerase is expressed in essentially all cancer cells, but not in normal somatic 
cells (Kim et al., 1994; Phatak & Burger, 2007), the inhibition of this enzyme is an attractive 
therapeutic strategy for selectively targeting brain tumors while sparing normal brain tissue. 
The human telomerase enzyme is a specialized ribonucleoprotein reverse transcriptase 
containing essential RNA (hTR) and protein (hTERT) subunits. Telomerase elongates 
telomeres by adding the (TTAGGG)n telomeric repeats to the ends of chromosomes, 
protecting the chromosome ends from fusion and DNA damage recognition (Feng et al., 
1995; Greider & Blackburn, 1985). During cell division in cancer cells, DNA is continuously 
extended or maintained by telomerase to compensate for the lost telomeric repeats resulting 
from the 'end-replication' problem of DNA polymerase (Levy et al., 1992; Röth et al., 2003).  
In the absence of telomerase activity, chromosome ends shorten with each cell division, 
eventually resulting in growth arrest or cell death, termed replicative senescence or crisis 
(Allsopp  et al., 1992; Shay & Wright, 2006). Although cancer cells express telomerase, these 
cells typically have relatively short but stable telomere length, whereas normal cells do not 
express telomerase and have long, slowly shortening telomeres. These differences between 
cancer and normal cells make cancer cells more sensitive to telomerase inhibitors, and may 
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allow for a substantial therapeutic window for telomerase inhibition-based treatments (Asai 
et al., 2003). 
GRN-163, a telomerase enzyme antagonist, is a 13-mer oligonucleotide N3'P5' 
thiophosphoramidate, that exhibits high RNA binding affinity for the targeted template 
region of hTR in a sequence-specific manner (Gryaznov et al., 2001; Herbert et al., 2002). 
GRN-163 has demonstrated potent inhibitory activity against human telomerase in several 
biochemical assays, with IC50 values of < 1 nM (Gryaznov et al., 2001; Herbert et al., 2002).  
In vitro, telomerase inhibition by GRN-163 induced cellular senescence and apoptosis in 
various human cancer cell lines (Ozawa et al., 2004; Asai et al., 2003; Herbert, 2002; Akiyama 
et al., 2003; Gryaznov et al., 2003; Wang et al., 2004). Although a potential limitation of 
oligonucleotide therapies is the bioavailability in tumor tissues (Corey, 2002), GRN-163 
inhibited tumor growth in prostate cancer, multiple myeloma, lymphoma, hepatoma and 
glioblastoma xenografts in rodents (Ozawa et al., 2004; Asai et al., 2003; Wang et al., 2004; 
Hashizume et al., 2008; Djojosubroto et al., 2005).  GRN-163 has been delivered successfully 
into the brain using IND and shown impressive oncolytic activity without harming normal 
brain tissue (Hashizume et al., 2008). Intranasally delivered GRN-163 exhibited favorable 
tumor uptake, inhibited tumor growth in human glioblastoma xenografts in rats and 
increased the survival of tumor-bearing animals. Following the IND of the highest possible 
dose of GRN-163 (0.65 μmol/μl, based on the solubility of the compound in saline solution), 
the compound could be detected in the cerebral hemispheres, brainstem and intracranial 
sections of the trigeminal nerve in naïve rats within 10 min of administration. In tumor-
bearing rats, GRN-163 was detected at the edge of the tumor after 30 min, and throughout 
the tumor between 4 and 24 h after administration (Figure 4).  
 
 
Fig. 4. Distribution of fluorescein-labeled GRN163 by IND into intracerebral tumors in 
athymic rats. Abbreviations: T, tumor; NB, normal brain. 
Importantly, very little or no GRN-163 was found in healthy brain cells adjacent to the 
tumor or in any other part of the brain. This apparent selectivity may be a result of the 
specific binding affinity that GRN-163 exhibits for tumor cell telomerase (Herbert et al., 
2002). The specificity achieved with IND appears to be superior to the results obtained using 
CED, which reportedly delivers drugs beyond the tumor boundary into adjacent healthy 
brain tissue, leading to damage to healthy sections of the brain (Kawakami et al., 2004; 
Mamot et al., 2004, Ozawa et al., 2004). In addition, intranasally delivered GRN-163 
inhibited telomerase activity in intracranial glioblastoma xenografts in rats in a dose-
dependent manner (Figure 5).  
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Fig. 5. Inhibition of telomerase activity by GRN163 in intracerebral GBM xenografts. 
Moreover, GRN-163 (qd for 12 days) delivered intranasally at the highest solubility dose 
significantly prolonged the median survival from 35 days in the control group to 75.5 days 
in the GRN163-treated group. None of the rats that were treated with GRN-163 exhibited 
signs of toxicity or behavioral abnormalities during the 12-day treatment period (Figure 6). 
 
 
Fig. 6. Survival of rats treated with intranasal GRN163. 
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Because the mechanism of action of oligonucleotide-based telomerase antagonists such as 
GRN-163 is through the competitive inhibition of the telomerase enzyme (Gryaznov et al., 
2001; Herbert et al., 2002), treated tumor cells can regain baseline telomerase activity 
following termination of treatment with the telomerase inhibitor. Thus, it is possible that 
telomerase inhibitor agents will need to be administered for an extended period of time to 
achieve efficacy. Hypothetically, repeated intranasal treatment is possible, and may be 
practical as a convenient self-administered treatment.  
The lipid-modified N3'P5' thiophosphoramidate oligonucleotide  imetelstat represents the 
most advanced anti-telomerase therapeutic, and is a more potent derivative of GRN-163 
(Herbert et al., 2005). Because of increased lipophilicity, imetelstat exhibits increased 
bioavailability and cellular uptake in tumors compared with nonlipidated compounds, and 
it is more acid-resistant than other telomerase-targeted phosphoramidate oligonucleotides 
(Herbert et al., 2005).  Imetelstat also inhibits telomerase activity in various tumor cell lines 
with IC50 values between 3 and 300 nM in the absence of any cellular uptake enhancers 
(Graznov et al., 2007). In cell-based studies with GRN-163, there was generally a phenotypic 
lag of at least a few weeks between the onset of exposure and growth inhibition (Akiyama et 
al., 2003); however, with imetelstat, the addition of a 5' lipid (palmitate) moiety increased 
potency and resulted in a more rapid loss of telomeres (population doubling [population 
doubling (PD) ~ 8 for GRN-163L-treated cells and PD ~ 13 for GRN-163-treated cells] and 
inhibition of cell growth (Herbert et al., 2005). In vivo inhibition of tumor growth by 
imetelstat has been reported in multiple animal models (Djojosubroto et al., 2005; Dikmen et 
al., 2005; Hochreiter et al., 2006; Marian et al., 2009) and Phase I/II clinical trials with 
imetelstat have been initiated in patients with chronic lymphocytic leukemia, refractory or 
relapsed solid tumors, NSCLC, multiple myeloma and breast cancer (Geron Corp., 2009). 
3.3.2 Limitations and future prospects of telomerase inhibition by IND as a therapy for 
GBM 
Although the inhibition of telomerase offers exciting therapeutic possibilities for the 
treatment of GBM patients, there are some potential limitations of this approach, such as the 
engagement of an alternative telomere-lengthening mechanism that can lead to anti-
telomerase treatment (Bollmann et al., 2007). In addition, anti-telomerase therapy may be 
associated with a delay in efficacy because of the lag period between the initiation of anti-
telomerase therapy (telomerase shortening) and the onset of therapeutically beneficial 
effects (cell death) (Bechter et al., 2004). The combination of IND of telomerase inhibitors 
with chemotherapy or radiotherapy may produce more rapid effects, and may provide an 
approach for minimizing the lag phase, potentially preventing or delaying tumor 
recurrences (Shay & Wright, 2006).  The combination of imetelstat with existing 
chemotherapeutic agents has been demonstrated to enhance chemosensitivity in various 
human cancer cells (Djojosubroto  et al., 2005; Godblatt et al., 2009a, 2009b). More 
specifically, imetelstat increased doxorubicin sensitivity of Hep3B human hepatoma cells 
(Djojosubroto  et al., 2005), sensitized human breast cancer cells to paclitaxel and 
trastuzumab (Godblatt et al., 2009a, 2009b), and also enhanced hyperthermia-mediated 
radiosensitization in human 293 cell lines (Gomez-Millan et al., 2007). Recently, imetelstat in 
combination with radiation and temozolomide had a statistically significant effect on cell 
survival and activated the DNA damage response pathway in GBM tumor-initiating cells 
(Marian et al., 2010).  
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Further potential limitations of oligonucleotide-based therapies using IND are the low 
bioavailability and absorption in the nasal mucosa and tumor tissues because of low 
permeability and solubility (Kausch & Böhle, 2003; Dias & Stein, 2002). The poor absorption 
of drugs across the nasal membrane is due to low permeability of the nasal membrane, 
mucociliary clearance, enzymatic degradation, and efflux mechanisms, such as P-
glycoprotein and ABC transporters (Dhuria et al., 2010). 
3.3.3 Intranasal delivery of liposomal therapeutic agents  
Liposomes can be used as biocompatible carriers to improve delivery properties across the 
nasal mucosa perhaps by increasing residence time of the formulation in the nasal cavity, 
resulting in higher concentration of encapsulated drugs in the brain. A study of IND with 
rivastigmine, an acetyl cholinesterase inhibitor, showed that the liposome drug formulation 
had a longer half-life compared to the free drug due to sustained release of rivastigmine 
from the liposomes (Arumugam et al., 2008). Migliore et al also reported that IND of the 
liposomal preparation resulted in a higher net delivery and longer retention of ovalbumin in 
the brain than the nonliposomal preparation (Migliore et al., 2010).  Increased tissue 
retention may be a consequence of the protein’s association with cationic lipids, rendering it 
more likely to undergo cellular binding and adsorptive endocytosis and impeding its 
diffusion and clearance from the brain (Kumagai et al., 1987). IND with liposomal 
therapeutic agents is conceptually attractive, and its appeal as a minimally invasive 
therapeutic strategy would facilitate its translation into clinical trials for the treatment of 
brain tumor patients. 
4. Conclusion  
IND of therapeutic agents is an innovative therapeutic strategy capable of targeting drug 
delivery to the brain for the treatment of brain tumors and could provide an alternative to 
systemic (intravascular) and/or direct (intraparechymal) drug administrations. IND is a 
practical and noninvasive method of bypassing the BBB, and is amenable to self-
administration by patients. This technique has demonstrated promising results in the 
treatment of human CNS neurological disorders and rodent brain tumor without obvious 
toxicity. IND with GRN-163, an oligonucleotide-based telomerase inhibitor, has exhibited 
impressive oncolytic activity without inducing toxicity to healthy tissue (Hashizume et al., 
2008). Data support further development of intranasal GRN-163 as a potential therapy for 
patients with brain tumors and perhaps as a means for treating multifocal brain tumors, 
such as metastatic brain tumors and/or pediatric brainstem tumors, which are less 
amenable to surgical procedures. A telomerase inhibitor, imetelstat, has reached clinical 
trials, and may therefore become a part of the available cancer therapeutic armamentarium 
in the future. IND can be further optimized by the use of liposomal drug carriers which 
provide stable encapsulation for various anticancer agents.  
Given the promising results from current animal studies, intranasal therapeutic agents 
would seem to be prime candidates for clinical trials in patients with brain tumors. Initial 
trials of intranasal perillyl alcohol have begun in patients with recurrent malignant gliomas, 
and a reduction in the size of the brain tumors has been reported (Da Fonseca et al., 2006a, 
2006b, 2008). 
www.intechopen.com
 New Therapeutic Strategies for the Treatment of Brain Tumor 
 
201 
5. References 
Abbott, N.J.; Patabendige, A.A.; Dolman, D.E.; Yusof, S.R. & Begley, D.J.  (2009). Structure 
and function of the blood-brain barrier. Neurobiology of disease. Vol. 37, No. 1, pp. 
(13-25). 
Aboody, K.S.; Brown, A.; Rainov, N.G.; Bower, K.A.; Liu, S.; Yang, W.; Small, J.E.; 
Herrlinger, U.; Ourednik, V.; Black, P.M.; Breakefield, X.O. & Snyder, E.Y.  (2000). 
Neural stem cells display extensive tropism for pathology in adult brain: Evidence 
from intracranial gliomas. Proceedings of the National Academy of Sciences of the United 
States of America. Vol. 97, No. 23, pp. (12846–12851). 
Akiyama, M.; Hideshima, T.; Shammas, M.A.; Hayashi, T.; Hamasaki, M.; Tai, Y.T.; 
Richardson, P.; Gryaznov, S.; Munshi, N.C. & Anderson, K.C. (2003). Effects of 
oligonucleotide N3'gP5' thio phosphoramidate (GRN163) targeting telomerase 
RNA in human multiple myeloma cells. Cancer Research. Vol. 63, No. 9, pp. (6187- 
6194). 
Allsopp, R.C.; Vaziri, H.; Patterson, C.; Goldstein, S.; Younglai, E.V.; Futcher, A.B.; Greider, 
C.W. & Harley, C.B. (1992). Telomere length predicts replicative capacity of human 
fibroblasts. Proceedings of the National Academy of Sciences of the United States of 
America. Vol. 89, No. 21, pp. (10114-10118). 
Arumugam, K.; Subramanian, G.S.; Mallayasamy, S.R.; Averineni, R.K.; Reddy, M.S. & 
Udupa, N. (2008). A study of rivastigmine  liposomes for delivery into the brain 
through intranasal route. Acta Pharmaceutica. Vol. 58, No. 3, pp. (287-297). 
Asai, A.; Oshima, Y.; Yamamoto, Y.; Uochi, T.A.; Kusaka, H.; Akinaga, S.;Yamashita, Y.; 
Pongracz, K.; Pruzan, R.; Wunder, E.; Piatyszek, M.; Li, S.; Chin, A.C.; Harley, C.B. 
& Gryaznov, S.M. (2003). A novel telomerase template antagonist (GRN163) as a 
potential anticancer agent. Cancer Research. Vol. 63, No. 14, pp. (3931-3939). 
Banks, W.A.; During, M.J. & Niehoff, M.L.  (2004).  Brain uptake of the glucagon like 
peptide-1 antagonist exendin(9-39) after intranasal administration. The Journal of 
pharmacology and experimental therapeutics. Vol. 309, No. 2, pp. (469-475). 
Baumgartner, T.; Heinrichs, M.; Vonlanthen, A.; Fischbacher, U. & Fehr, E. (2008).  Oxytocin 
shapes the neural circuitry of trust and trust adaptation in humans. Neuron. Vol. 58, 
No. 4, pp. (639–650). 
Bechter, O.E.; Zou, Y.; Walker, W.; Wright, W.E. & Shay, J.W. (2004). Telomeric 
recombination in mismatch repair deficient human colon cancer cells after 
telomerase inhibition. Cancer Research. Vol. 64, No. 10, pp. (3444-3451). 
Benedict, C.; Hallschmid, M.; Hatke, A.; Schultes, B.; Fehm, H.L.; Born, J. & Kern, W. (2004). 
Intranasal insulin improves memory in humans. Psychoneuroendocrinology. Vol. 29, 
No. 10, pp. (1326-1334). 
Bidros, D.S. & Vogelbaum, M.A. (2009). Novel drug delivery strategies in neuro-oncology. 
Neurotherapeutics. Vol. 6, No. 3, pp. (539–546). 
Bollmann, F.M. (2007). Targeting ALT: The role of alternative lengthening  of telomeres in 
pathogenesis and prevention of cancer. Cancer Treatment Reviews. Vol. 33, No. 8, pp. 
(704-709). 
Boockvar, J.A.; Tsiouris, A.J.; Hofstetter, C.P.; Kovanlikaya, I.; Fralin, S.; Kesavabhotla, K.; 
Seedial, S.M.; Pannullo, S.C.; Schwartz, T.H.; Stieg, P.; Zimmerman, R.D.; 
Knopman, J.; Scheff, R.J.; Christos, P.; Vallabhajosula, S. & Riina, H.A. (2010).  
Safety and maximum tolerated dose of superselective intraarterial cerebral infusion 
www.intechopen.com
 Brain Tumors - Current and Emerging Therapeutic Strategies 
 
202 
of bevacizumab after osmotic blood-brain barrier disruption for recurrent 
malignant glioma.  Journal of  Neurosurgery. Vol. 114, No. 3, pp. (624-632). 
Brightman, M.W. (1977). Morphology of blood–brain interfaces. Experimental eye research. 
Vol. 25, pp. (1–25). 
CBTRUS statistical report tables: Brain Tumor Registry of The United States, Hinsdale, IL, 
USA, In: CBTRUS, (accessed April 12th 2011). http://www.cbtrus.org/2010-NPCR-
SEER/Table23.pdf 
Choi, Y.K. & Kim, K.W. (2008). Blood-neural barrier: its diversity and  coordinated cell-to-
cell communication. BMB Reports. Vol. 41, No.  5, pp. (345-352). 
Coomber, B.L.; Stewart, P.A.; Hayakawa, K.; Farrell, C.L. & Del Maestro, R.F.  (1985). 
Quantitative morphology of human glioblastoma   multiforme microvessels: 
structural basis of blood-brain barrier defect. Journal of Neuro-oncology. Vol. 5, No. 4, 
pp. (299–307). 
Corey, D.R. (2002). Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene. Vol. 
21, No. 4, pp. (631-637). 
Da Fonseca, C.O.; Landeiro, J.A.; Clark, S.S.; Quirico-Santos, T.; da Costa Carvalho Mda, G. 
& Gattass, C.R.  (2006). Recent advances in the molecular genetics of malignant 
gliomas disclose targets for antitumor agent perillyl alcohol.  Surgical Neurology. 
Vol. 65, pp. (S1:2-S1:9).  
Da Fonseca, C.O.; Masini, M.; Futuro, D.; Caetano, R.; Gattass, C.R. & Quirico-Santos, T.  
(2006). Anaplastic oligodendroglioma responding favorably to intranasal delivery 
of perillyl alcohol: a case report and literature review. Surgical Neurology. Vol. 66, 
No. 6, pp. (611-615). 
Da Fonseca CO, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T, Gattass 
CR.  (2008). Preliminary results from a phase I/II study of perillyl alcohol 
intranasal administration in adults with recurrent malignant gliomas. Surgical 
Neurology. Vol. 70, No. 3, pp. (259-267). 
Danielyan, L.; Schäfer, R.; von Ameln-Mayerhofer, A.; Buadze, M.; Geisler, J.; Klopfer, T.; 
Burkhardt, U.; Proksch, B.; Verleysdonk, S.; Ayturan, M.; Buniatian, G.H.; Gleiter, 
C.H.; Frey, W.H. 2nd. (2009). Intranasal delivery of cells to the brain. European 
Journal of Cell Biology. Vol. 88, No. 6, pp. (315-324). 
Dias, N. & Stein, C.A. (2002). Potential roles of antisense oligonucleotides in cancer therapy. 
The example of Bcl-2 antisense oligonucleotides. European journal of pharmaceutics 
and biopharmaceutics. Vol. 54, No. 3, pp. (263-269). 
Deeken, J.F. & Loscher, W.  (2007). The blood-brain barrier and cancer: transporters, 
treatment and Trojan horses. Clinical  Cancer Research,   Vol. 13, No. 6, pp. (1663-
1674). 
Dhuria, S.V.; Hanson, L.R. & Frey, W.H. 2nd. (2010).   Intranasal delivery to the central 
nervous system: mechanisms and experimental considerations. Journal of 
Pharmaceutical Sciences. Vol. 99, No. 4, pp. (1654-1673). 
Dhanda, D.; Frey, W.H. 2nd.; Leopold, D. & Kompella, U.B.  (2006).  Approaches for drug 
deposition in the human olfactory epithelium. Drug Delivery Technology. Vol. 5, No. 
4, pp. (64-72). 
Dikmen, Z.G.; Gellert, G.C.; Jackson, S.; Gryaznov, S.; Tressler, R.; Dogan, P.; Wright, W.E. & 
Shay, J.W. (2005). In vivo inhibition of lung cancer by GRN163L: A novel human 
telomerase inhibitor. Cancer Research. Vol. 65, No. 17, pp. (7866-7873). 
www.intechopen.com
 New Therapeutic Strategies for the Treatment of Brain Tumor 
 
203 
Djojosubroto, M.W.; Chin, A.C.; Go, N.; Schaetzlein, S.; Manns, M.P.; Gryaznov, S.; Harley, 
C.B. & Rudolph, K.L.  (2005). Telomerase antagonists GRN163 and GRN163L 
inhibit tumor growth and increase chemosensitivity of human hepatoma. 
Hepatology. Vol. 42, No. 5, pp. (1127-1136). 
Domes, G.; Heinrichs, M.; Glascher, J.; Buchel, C.; Braus, D.F. & Herpertz, S.C.  (2007).  
Oxytocin attenuates amygdala responses to emotional faces regardless of valence. 
Biological Psychiatry.  Vol. 62 No. 10, pp. (1187–1190). 
Domes, G.; Heinrichs, M.; Michel, A.; Berger, C. & Herpertz, S.C.  (2007). Oxytocin improves 
‘‘mind-reading’’ in humans. Biological Psychiatry Vol. 61, No. 6, pp. (731–733). 
Ekstrand, A.J.; James, C.D.; Cavenee, W.K.; Seliger, B.; Pettersson, R.F. & Collins, V.P.  
(1991).  Cancer Research.  Vol. 51, No. 8, pp. (2164-2172). 
ElBayoumi, T.A. & Torchilin, V.P. (2009). Tumor-targeted nanomedicines: enhanced 
antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes 
modified with cancer-specific monoclonal antibody. Clinical Cancer Research.  Vol. 
15, No. 6, pp. (1973-1980). 
Eyal, S, Hsiao, P. & Unadkat, J.D. (2009). Drug interactions at the blood- brain barrier: fact or 
fantasy? Pharmacology & Therapeutics. Vol. 123, No. 1, pp. (80-104). 
Frank, R.T.; Edmiston, M.; Kendall, S.E.; Najbauer, J.; Cheung, C.W.; Kassa, T.; Metz, M.Z.; 
Kim, S.U.; Glackin, C.A.; Wu, A.M.; Yazaki, P.J. & Aboody, K.S. (2009). Neural stem 
cells as a novel platform for  tumor-specific delivery of therapeutic antibodies. 
Public Library of  Science one. Vol. 4, No. 12, pp. e8314. 
Feng, J.; Funk, W.D.; Wang, S.S.; Weinrich, S.L.; Avilion, A.A.; Chiu, C.P.; Adams, R.R.; 
Chang, E.; Allsopp, R.C. & Yu, J. (1995). The RNA component of human telomerase. 
Science. Vol. 269, No. 5228, pp. (1236-1241). 
Gabizon, A.; Shmeeda, H. & Barenholz, Y.  (2003). Pharmacokinetics of pegylated liposomal 
Doxorubicin: review of animal and human  studies. Clinical pharmacokinetics.  Vol. 
42, No. 5, pp. (419-436). 
Geron Corp, Menlo Park, CA, USA, (2009). Telomerase inhibitor drug – Imetelstat 
(GRN163L): www.geron.com/patients/clinicaltrials/   GRN163L.aspx 
Gerstner, E.R. & Fine, R.L. (2007). Increased permeability of the blood-brain barrier to 
chemotherapy in metastatic brain tumors: establishing a treatment paradigm. 
Journal of Clinical Oncology. Vol. 25, No. 16,  pp. (2306-2312). 
Godblatt, E.M.; Erickson, P.A.; Gentry, E.R.; Gryaznov, S.M. & Herbert, B.S. (2009).  Lipid-
conjugated telomerase template antagonists sensitize resistant HER2-positive 
breast cancer cells to trastuzumab. Breast Cancer Research and Treatment. Vol. 118, 
No. 1,   pp. (21-32). 
Goldblatt, E.M.; Gentry, E.R.; Fox, M.J.; Gryaznov, S.M.; Shen, C. &   Herbert, B.S. (2009).  
The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer 
cell morphology, inhibits growth, and augments the effects of paclitaxel. Molecular   
Cancer Therpeutics. Vol. 8, No. 7, pp. (2027-2035).  
Gomez-Millan, J.; Goldblatt, E.M.; Gryaznov, S.M.; Mendonca, M.S. & Herbert, B.S. (2007). 
Specific telomere dysfunction induced by GRN163L increases radiation sensitivity 
in breast cancer cells.International journal of radiation oncology, biology, physics. Vol. 
67, No. 3, pp. (897-905). 
Guastella, A.J.; Mitchell, P.B. & Dadds, M.R. (2008). Oxytocin increases gaze to the eye 
region of human faces. Biological Psychiatry. Vol. 63, No.   1, pp. (3–5). 
www.intechopen.com
 Brain Tumors - Current and Emerging Therapeutic Strategies 
 
204 
Graznov, S.M.; Jackson, S.; Dikmen, G.; Harley, C.; Herbert, B.S.; Wright, W.E.; Shay, J.W. 
(2007).  Oligonucleotide conjugate GRN163L targeting human telomerase as 
potential anticancer and antimetastatic agent. Nucleosides Nucleotides and Nucleic 
Acids. Vol.  26, No. 10-12, pp. (1577-1579). 
Greenwood, J. (1992). Experimental manipulation of the blood–brain and blood–retinal 
barriers. In Physiology and Pharmacology of the Blood–Brain Barrier. Handbook of 
Experimental Pharmacology, Bradbury, M.W.B. and Abbott, N.J., pp. 459–486, 
Springer-Verlag,   Berlin, Germany 
Gryaznov,  S.M.; Pongracz, K.; Matray, T.; Schultz, R.; Pruzan, R.; Aimi, J.; Chin, A.; Harley, 
C.; Shea-Herbert, B.; Shay, J.; Oshima, Y.; Asai, A. & Yamashita, Y. (2001). 
Telomerase inhibitors – Oligonucleotide phosphoramidates as potential therapeutic   
agents. Nucleosides Nucleotides and Nucleic Acids. Vol. 20, No. 4-7,   pp. (401-410). 
Greider, C.W. & Blackburn, E.H. (1985). Identification of a specific telomere terminal 
transferase activity in Tetrahymena extracts. Cell. Vol. 43,   No. 2, Pt 1, pp. (405-413). 
Hashizume, R.; Ozawa, T.; Gryaznov, S.M.; Bollen, A.W.; Lamborn. K.R.; Frey, W.H. 2nd & 
Deen, D.F. (2008). New therapeutic approach for brain tumors: Intranasal delivery 
of telomerase inhibitor GRN163. Neuro-Oncology. Vol. 10, No. 2, pp. (112-1120). 
Herbert, B.S.; Gellert, G.C.; Hochreiter, A.; Pongracz, K.; Wright, W.E.; Zielinska, D.; Chin, 
A.C.; Harley, C.B.; Shay, J.W. & Gryaznov, S.M. (2005).  Lipid modification of 
GRN163, an N3'gP5' thio- phosphoramidate oligonucleotide, enhances the potency 
of  telomerase inhibition. Oncogene. Vol. 24, No. 33, pp. (5262-5268). 
Herbert, B.S.; Pongracz, K.; Shay, J.W. & Gryaznov, S.M. (2002). Oligonucleotide N3'gP5' 
phosphoramidates as efficient   telomerase inhibitors. Oncogene. Vol. 21, No. 4, pp. 
(638-642). 
Hochreiter, A.E.; Xiao, H.; Goldblatt, E.M.; Gryaznov, S.M.; Miller, K.D.; Badve, S.; Sledge, 
G.W. & Herbert, B.S. (2006). Telomerase template antagonist GRN163L disrupts 
telomere maintenance, tumor growth, and metastasis of breast cancer. Clinical 
Cancer Research. Vol. 12, No. 10, pp. (3184-3192). 
Huynh, G.H.; Deen, D.F. & Szoka, F.C. Jr. (2006). Barriers to carrier   mediated drug and 
gene delivery to brain tumors. Journal of   Control Release.   Vol. 110, No. 2, pp. (236-
259). 
Kausch, I. & Böhle, A. (2003). Antisense oligonucleotide therapy for urologic tumors. Current 
Urology Reports. Vol. 4, No. 1, pp. (60-69). 
Kawakami, K.; Kawakami, M.; Kioi, M.; Husain, S.R. & Puri, R.K. (2004). Distribution 
kinetics of targeted cytotoxin in glioma by bolus or   convection-enhanced delivery 
in a murine model.Journal of Neurosurgery. Vol. 101, No. 6, pp. (1004-1011). 
Kim, N.W.; Piatyszek, M.A.; Prowse, K.R.; Harley, C.B.; West, M.D.; Ho, P.L.; Coviello, 
G.M.; Wright, W.E.; Weinrich, S.L. & Shay,J.W.  (1994).  Specific association of 
human telomerase activity with  immortal cells and cancer. Science. Vol. 266, No. 
5193, pp. (2011-2015). 
Kirsch, P.; Esslinger, C.; Chen, Q.; Mier, D.; Lis, S.; Siddhanti, S.; Gruppe, H.; Mattay, V.S.; 
Gallhofer, B. & Meyer-Lindenberg, A.  (2005).  Oxytocin modulates neural circuitry 
for social cognition and fear in humans. The Journal of Neuroscience.  Vol. 25,  No. 49, 
pp. (11489–11493). 
Kosfeld, M.; Heinrichs, M.; Zak, P.J.; Fischbacher, U. & Fehr, E. (2005). Oxytocin increases 
trust in humans. Nature. Vol. 435, No. 7042, pp. (673-676). 
www.intechopen.com
 New Therapeutic Strategies for the Treatment of Brain Tumor 
 
205 
Kumagai, A.K.; Eisenberg, J.B. & Pardridge, W.M. (1987). Absorptive-mediated endocytosis 
of cationized albumin and a b- endorphin-cationized albumin chimeric peptide by 
isolated brain   capillaries. Model system of blood-brain barrier transport. The 
Journal of Biological Chemistry. Vol. 262, No. 31, pp. (15214–15219). 
Levy, M.Z.; Allsopp, R.C.; Futcher, A.B.; Greider, C.W. & Harley, C.B.   (1992).  Telomere 
end-replication problem and cell aging. Journal  of Molecular Biology. Vol. 225, No. 4, 
pp. (951-960). 
MacKay, J.A.; Deen, D.F. & Szoka, F.C. Jr. (2005). Distribution in brain of  liposomes after 
convection enhanced delivery; modulation by   particle charge, particle diameter, 
and presence of steric coating.   Brain Research. Vol. 1035, No. 2, pp. (139-153). 
Mamot, C.; Drummond, D.C.; Noble, C.O.; Kallab, V.; Guo, Z.; Hong, K.,  Kirpotin, D.B. & 
Park, J.W. (2005). Epidermal growth factor   receptor-targeted immunoliposomes 
significantly enhance the efficacy of multiple anticancer drugs in vivo.  Cancer 
Research.  Vol. 65, No. 24, pp. (11631-11638). 
Mamot, C.; Nguyen, J.B.; Pourdehnad, M.; Hadaczek, P.; Saito, R.; Bringas,  J.R.; Drummond, 
D.C.; Hong, K.; Kirpotin, D.B.; McKnight, T.; Berger, M.S.; Park, J.W. & Bankiewicz, 
K.S. (2004). Extensive distribution of liposomes in rodent brains and brain tumors 
following convection-enhanced delivery. Journal of Neuro- Oncology. Vol. 68, No. 1, 
pp. (1-9). 
Marian, C.O.&  Shay, J.W. (2009). Prostate tumor-initiating cells: A new target for telomerase 
inhibition therapy? Biochimica et biophysica acta. Vol. 1792, No. 4, pp. (289-296). 
Marian, C.O.; Cho, S.K.; McEllin, B.M.; Maher, E.A.; Hatanpaa, K.J.; Madden, C.J.; Mickey, 
B.E.; Wright, W.E.; Shay, J.W.; Bachoo, R.M. (2010).  The telomerase antagonist, 
imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to 
decreased proliferation and tumor growth. Clinical Cancer Research. Vol. 16, No. 1, 
pp. (154-163). 
Migliore, M.M.; Vyas, T.K.; Campbell, R.B.; Amiji, M.M. & Waszczak, B.L. (2010). Brain 
delivery of proteins by the intranasal route of administration: a comparison of 
cationic liposomes versus   aqueous solution formulations. Journal of Pharmaceutical 
Sciences. Vol. 99, No. 4, pp. (1745-1761). 
Moreau P. (2009). Combination regimens using doxorubicin and pegylated liposomal 
doxorubicin prior to autologous transplantation in multiple myeloma. Expert review 
of anticancer therapy. Vol. 9, No. 7, pp. (885-890). 
Murad GJ, Walbridge S, Morrison PF, Garmestani K, Degen JW, Brechbiel MW, Oldfield EH, 
Lonser RR. (2006). Real-time, image-guided,  convection-enhanced delivery of 
interleukin 13 bound to   pseudomonas exotoxin. Clinical Cancer Research. Vol. 12, 
No. 10, pp. (3145-3151). 
Murramatsu, K.; Maitani, Y.; Takayama, K. & Nagai, T. (1999). The   relationship between 
the rigidity of the liposomal membrane and  
the absorption of insulin after nasal administration of liposomes modified with an enhancer 
containing insulin in rabbits. Drug development and industrial pharmacy. Vol. 25, No. 
10, pp. (1099-1105). 
Noble, C.O.; Krauze, M.T.; Drummond, D.C.; Yamashita, Y.; Saito, R.; Berger, M.S.; Kirpotin, 
D.B.; Bankiewicz, K.S. & Park, J.W. (2006). Novel Nanoliposomal CPT-11 Infused 
by Convection-Enhanced Delivery in Intracranial Tumors: Pharmacology and 
Efficacy. Cancer Research. Vol. 66, No. 5, pp. (2801-2806). 
www.intechopen.com
 Brain Tumors - Current and Emerging Therapeutic Strategies 
 
206 
Ozawa, T.; Wang, J.; Hu, L.J.; Bollen, A.W.; Lamborn, K.R. & Deen, D.F. (2002).  Growth of 
human glioblastomas as xenografts in the   brains of athymic rats. In Vivo. Vol. 16, 
No. 1, pp. (55-60). 
Ozawa, T.; Gryaznov, S.M.; Hu, L.J.; Pongracz, K.; Santos, R.A.; Bollen, A.W.; Lamborn, K.R. 
& Deen, D.F. (2004). Antitumor effects of specific telomerase inhibitor GRN163 in 
human glioblastoma   xenografts. Neuro-Oncology. Vol. 6, No 3, pp. (218-226). 
Parker, K.J.; Buckmaster, C.L.; Schatzberg, A.F. & Lyons, D.M. (2005).  Intranasal oxytocin 
administration attenuates the ACTH stress response in monkeys. 
Psychoneuroendocrinology. Vol. 30, No. 9, pp. (924-929). 
Pardridge, W.M. (1999). Non-invasive drug delivery to the human brain using endogenous 
blood–brain barrier transport systems. Pharmaceutical science & technology today. Vol. 
2, No. 2, pp. (49–59). 
Pardridge, W.M.  (2007).  Blood-brain barrier delivery. Drug Discovery   Today. Vol. 12, No 1–
2, pp. (54–61). 
Phatak, P. & Burger, A.M. (2007). Telomerase and its potential for   therapeutic intervention. 
British Journal of Pharmacology. Vol. 152,   No. 7, pp. (1003-1011). 
Rapoport, S.I. (1996). Modulation of blood–brain barrier permeability.Journal of Drug 
Targeting. Vol. 3, No. 6, pp. (417–425). 
Reger, M.A.; Watson, G.S.; Green, P.S.; Wilkinson, C.W.; Baker, L.D.; Cholerton, B.; Fishel, 
M.A.; Plymate, S.R.; Breitner, J.C.; DeGroodt, W.; Mehta, P. & Craft, S. (2008). 
Intranasal insulin improves cognition and modulates beta-amyloid in early AD. 
Neurology. Vol. 70, No. 6, pp. (440-448). 
Rimmele U, Hediger K, Heinrichs M, Klaver P: Oxytocin makes a face in memory familiar. 
Jouranl of Neuroscience (2009). 29 (1): 38–42. 
Röth, A.; Vercauteren, S.; Sutherland, H.J. & Lansdorp, P.M. (2003). Telomerase is limiting 
the growth of acute myeloid leukemia cells. Leukemia. Vol. 17, No. 12, pp. (2410-
2417). 
Rousselle, C.; Clair, P.; Lefauconnier, J.M.; Kaczorek, M.; Scherrmann, J.M.    & Temsamani, 
J.  (2000). New advances in the transport of     doxorubicin through the blood–brain 
barrier by a peptide vector-   mediated strategy. Molecular Pharmacology. Vol. 57, 
No. 4, pp.   (679–686). 
Sakane, T.; Yamashita, S.; Yata, N. & Sezaki, H. (1999). Transnasal delivery of 5-fluorouracil 
to the brain in the rat. Journal of Drug Targeting. Vol. 7, No. 3, pp. (233-240). 
Saito, R.; Bringas, J.R.; Panner, A.; Tamas, M.; Pieper, R.O.; Berger, M.S. &   Bankiewicz, K.S.  
(2004). Convection-enhanced delivery of tumor   necrosis factor-related apoptosis-
inducing ligand with systemic   administration of temozolomide prolongs survival 
in an   intracranial glioblastoma xenograft model.  Cancer Research. Vol.   64, No. 19, 
pp. (6858-6862). 
Saito, R.; Krauze, M.T.; Noble, C.O.; Tamas, M.; Drummond, D.C.; Kirpotin,   D.B.; Berger, 
M.S.; Park, J.W. & Bankiewicz, K.S. (2006). Tissue   affinity of the infusate affects the 
distribution volume during   convection-enhanced delivery into rodent brains: 
Implications for   local drug delivery. Journal of neuroscience methods. Vol. 154, No. 1-
2, pp. (225-232). 
Sampson, J.H.; Akabani, G.; Archer, G.E.; Berger, M.S.; Coleman, R.E.; Friedman, A.H.; 
Friedman, H.S.; Greer, K.; Herndon, J.E. 2nd; Kunwar, S.; McLendon, R.E.; Paolino, 
A.; Petry, N.A.; Provenzale, J.M.; Reardon, D.A.; Wong, T.Z.; Zalutsky, M.R.; 
www.intechopen.com
 New Therapeutic Strategies for the Treatment of Brain Tumor 
 
207 
Pastan, I. & Bigner, D.D. (2008). Intracerebral infusion of an EGFR-targeted    toxin 
in recurrent malignant brain tumors. Neuro-Oncology. Vol.   10, No. 3, pp. (320-329). 
Sandberg, D.I.; Edgar, M.A. & Souweidane, M.M. (2002). Convection-enhanced delivery into 
the rat brainstem. Journal of Neurosurgery. Vol. 96, No. 5, pp. (885-891). 
Saunders,  N.R.; Ek, C.J.; Habgood, M.D. & Dziegielewska, K.M. (2008). Barriers in the brain: 
a renaissance? Trends in Neurosciences. Vol. 31, No. 6, pp. (279-286). 
Schlosshauer, B. (1993). The blood–brain barrier: morphology, molecules, and neurothelin. 
Bioassays. Vol. 1, pp. (341–346). 
Serwer, L.; Hashizume, R.; Ozawa, T. and James, C.D.  (2010).  Systemic and local drug 
delivery for treating diseases of the central nervous system in rodent models. 
Journal of visualized experiments.  Vol. 42,   pii: 1992. doi: 10.3791/1992. 
Shay, J.W. & Wright, W.E. (2006). Telomerase therapeutics for cancer: Challenges and new 
directions. Nature Reviews Drug Discovery.   Vol. 5, No. 7, pp. (577-584). 
Shingaki, T.; Sakane, T.; Yamashita, S.; Sezaki, H.; Yoshiharu, T.; Shoubu, S. (1999). 
Transnasal delivery of anticancer drugs to the brain tumor: A new strategy for 
brain tumor chemotherapy. Drug Delivery System. Vol. 14, No. 5, pp. (365-371). 
Shingaki, T.; Inoue, D.; Furubayashi, T.; Sakane, T.; Katsumi, H.; Yamamoto, A. & 
Yamashita, S.  (2010). Transnasal Delivery of Methotrexate to Brain Tumors in Rats: 
A New Strategy for Brain Tumor Chemotherapy. Molecular Pharmaceutics. Vol. 7, 
No. 5, pp. (1561–1568). 
Tamai, I. & Tsuji, A. (1996). Drug delivery through the blood–brain barrier. Advanced drug 
delivery reviews. Vol. 19, pp. (401–424).  
Tai, C. & Kasahara, N. (2008). Replication-competent retrovirus vectors for   cancer gene 
therapy. Frontiers in Bioscience.  Vol. 13, pp. (3083-3095). 
Tanguay, J.S.; Ansari, J.; Buckley, L. & Fernando, I.  (2009).  Epithelial ovarian cancer: role of 
pegylated liposomal Doxorubicin in prolonging the platinum-free interval and 
cancer antigen 125 trends during treatment. International journal of gynecological 
cancer, Vol. 19, No. 3, pp. (361-366). 
Thorne, R.G.; Pronk, G.J.; Padmanabhan, V. & Frey, W.H. 2nd. (2004). Delivery of insulin-
like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal 
pathways following intranasal administration. Neuroscience. Vol. 127, No. 2, pp. 
(481-496). 
Thorne, R.G., Hanson, L.R.; Ross, T.M.; Tung, D. & Frey, W.H. 2nd. (2008). Delivery of 
interferon-beta to the monkey nervous system following intranasal administration. 
Neuroscience.  Vol. 152, No. 3, pp. (785-797). 
United States National Institutes of Health, In: Clnicaltrial.gov, (accessed April 12th 2011), 
http://clinicaltrials.gov/ct2/results?term=Convection-enhanced+delivery 
Wang, D.; Gao, Y. & Yun, L. (2005). Study on brain targeting of raltitrexed following 
intranasal administration in rats. Cancer Chemotherpy and  Pharmacology. Vol. 57, No. 
1, pp. (1-8). 
Wang, E.S.; Wu, K.; Chin, A.C.; Chen-Kiang, S.; Pongracz, K.; Gryaznov, S.;    & Moore, M.A. 
(2004). Telomerase inhibition with an oligonucleotide telomerase template 
antagonist: In vitro and in   vivo studies in multiple myeloma and lymphoma. Blood. 
Vol. 103, No. 1. pp. (258-266). 
Yamashita, Y.; Krauze, M.T.; Kawaguchi, T.; Noble, C.O.; Drummond, D.C.; Park, J.W. & 
Bankiewicz, K.S.  (2007).  Convection-enhanced  delivery of a topoisomerase I 
www.intechopen.com
 Brain Tumors - Current and Emerging Therapeutic Strategies 
 
208 
inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated 
liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-Oncology. Vol. 
9, No. 1, pp. (20–28). 
Yong, R.L.; Shinojima, N.; Fueyo, J.; Gumin, J.; Vecil, G.G.; Marini, F.C.; Bogler, O.; Andreeff, 
M. & Lang, F.F. (2009). Human bone marrow-derived mesenchymal stem cells for 
intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. 
Cancer Research. Vol. 69, No. 23, pp. (8932–8940). 
Zhang, Y.; Zhang, Y.F.; Bryant, J.; Charles, A.; Boado, R.J. & Pardridge, W.M. (2004). 
Intravenous RNA interference gene therapy targeting the human epidermal growth 
factor receptor prolongs survival in intracranial brain cancer. Clinical Cancer 
Research. Vol. 10, No. 11, pp. (3667–3677). 
www.intechopen.com
Brain Tumors - Current and Emerging Therapeutic Strategies
Edited by Dr. Ana Lucia Abujamra
ISBN 978-953-307-588-4
Hard cover, 422 pages
Publisher InTech
Published online 23, August, 2011
Published in print edition August, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Brain Tumors: Current and Emerging Therapeutic Strategies focuses on tumor models, the molecular
mechanisms involved in the pathogenesis of this disease, and on the new diagnostic and treatment strategies
utilized to stage and treat this malignancy. A special section on immunotherapy and gene therapy provides the
most up-to-date information on the pre-clinical and clinical advances of this therapeutic venue. Each chapter in
Brain Tumors: Current and Emerging Therapeutic Strategies is authored by international experts with
extensive experience in the areas covered.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Rintaro Hashizume (2011). New Therapeutic Strategies for the Treatment of Brain Tumor, Brain Tumors -
Current and Emerging Therapeutic Strategies, Dr. Ana Lucia Abujamra (Ed.), ISBN: 978-953-307-588-4,
InTech, Available from: http://www.intechopen.com/books/brain-tumors-current-and-emerging-therapeutic-
strategies/new-therapeutic-strategies-for-the-treatment-of-brain-tumor
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
